Lung Cancer Clinical Trials

CLINICAL TRIAL 17723
Radiomics and Non-Imaging Biomarkers in Lung Cancer Screening and Early Detection
Condition: Thoracic
Intervention:

CLINICAL TRIAL 20386
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Condition: Thoracic
Intervention: Difluoromethylornithine (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20530
NAUTIKA1: A MULTICENTER, PHASE II, NEOADJUVANT AND ADJUVANT STUDY OF MULTIPLE THERAPIES IN BIOMARKER-SELECTED PATIENTS WITH RESECTABLE STAGES IB-III NON-SMALL CELL LUNG CANCER
Condition: Thoracic
Intervention:

CLINICAL TRIAL 20767
Integration of Immunotherapy into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Gemzar (gemcitabine); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); gemcitabine (); paclitaxel ()

CLINICAL TRIAL 21027
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
Condition: Thoracic
Intervention: Acyclovir (); Diphenhydramine (); Fluconazole (); H1 Histamine Antagonist (); IL-2 (Interleukin-2); LN-145 (); MESNA (); Neupogen (filgrastim); Valacyclovir (); acetaminophen (); cyclophosphamide (); cytoxan (cyclophosphamide); filgrastim ()

CLINICAL TRIAL 20938
A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Condition: Thoracic
Intervention: Not Applicable (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 21074
A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFRMutant cfDNA in Plasma After Initiation of Osimertinib
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); Alimta (Pemetrexed); Osimertinib (); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()

CLINICAL TRIAL 21184
Thoracic Program Trial Selection Protocol
Condition: Thoracic
Intervention:

CLINICAL TRIAL 21399
Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); MEM-288 (); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Taxotere (docetaxel); docetaxel ()

CLINICAL TRIAL 21589
BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing
Condition: Immunotherapy
Intervention:

CLINICAL TRIAL 21586
LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer
Condition: Thoracic
Intervention:

CLINICAL TRIAL 21626
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Condition: Thoracic
Intervention: Alimta (Pemetrexed); MK-1084 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin ()

CLINICAL TRIAL 21630
Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab with or without Chemotherapy in Black Patients with NSCLC
Condition: Thoracic
Intervention: Abraxane (); Alimta (Pemetrexed); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); paclitaxel ()

CLINICAL TRIAL 21951
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (STAR-121)
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Domvanalimab (); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); Zimberelimab (); carboplatin (); cisplatin (); paclitaxel ()

CLINICAL TRIAL 21971
Phase I Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients with Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); MESNA (); Nivolumab (Opdivo); Proleukin (Interleukin-2); TIL (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22079
A Phase 1/2, Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOC-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
Condition: Cutaneous
Intervention: IL-2 (Interleukin-2); IOV-4001 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22305
First-in-Human Study of STX-478, a Mutant-Selective PI3Ka Inhibitor as Monotherapy and in Combination with Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: 772256 (Palbociclib); Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Ribociclib (); STX478-101 (); fulvestrant ()

CLINICAL TRIAL 22441
An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Condition: Thoracic
Intervention: Alimta (Pemetrexed); ORIC-114 (); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()

CLINICAL TRIAL 22540
A Phase 1, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-130037, a Kelch-like ECH-associated protein 1 (KEAP1) activator, in participants with advanced solid tumors
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); Taxol (paclitaxel); Taxotere (docetaxel); VVD-130037 (); docetaxel (); paclitaxel ()

CLINICAL TRIAL 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (); RMC-9805 ()

CLINICAL TRIAL 23160
A Phase 2 Study of Alisertib in Patients with Extensive Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: Alisertib (MLN8237); G-CSF ()

CLINICAL TRIAL 23066
An Open-Label, Multi-Center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-Targeting T Cell Engager, in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer and in Patients with Other Relapsed/Refractory Neuroendocrine Carcinoma DAREON-5
Condition: Gastrointestinal Tumor
Intervention: BI 764532 ()

CLINICAL TRIAL 23182
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); Placebo (); V940 ()

CLINICAL TRIAL 23094
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination with Cemiplimab (Anti-PD-1 antibody) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 >=50%
Condition: Thoracic
Intervention: Cemiplimab (); Fianlimab (); Placebo (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 23180
A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-line Induction or Maintenance, in Subjects with Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); DS-7300a (I-DXd); I-DXd (); Paraplatin (carboplatin); carboplatin ()

CLINICAL TRIAL 23132
A Phase 1 Study of SGN-EGFRd2 in Advanced Solid Tumors
Condition: Gastrointestinal Tumor
Intervention: SGN-EGFRd2 (PF-08046052)

CLINICAL TRIAL 23179
Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients Throughout Florida
Condition: Multiple
Intervention:

CLINICAL TRIAL 23183
A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); RMC-6236 (); RMC-6291 (); RMC-9805 (); carboplatin (); cisplatin ()

CLINICAL TRIAL 23199
SR2204: A Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults with Lung Cancer and their Family Caregivers
Condition: Thoracic
Intervention:

CLINICAL TRIAL 23200
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Condition: Multiple
Intervention: memantine ()

CLINICAL TRIAL 23371
Ethnicity and Lung Cancer Survival: A Test of the Hispanic Sociocultural Hypothesis
Condition: Thoracic
Intervention:

CLINICAL TRIAL 23319
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); paclitaxel ()

CLINICAL TRIAL 23378
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of AVZO-021 as a single agent and in combination therapy in patients with advanced solid tumors
Condition: Breast
Intervention: 772256 (Palbociclib); AVZO-021 (); Abemaciclib (); Faslodex (fulvestrant); Femara (Letrozole); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Paraplatin (carboplatin); Ribociclib (); Sacituzumab Govitecan (); carboplatin (); fulvestrant ()

CLINICAL TRIAL 23380
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod CAR T, in Heterozygous HLA-A*02 Adult with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Condition: Thoracic
Intervention: A2B694 (); IL-2 (Interleukin-2); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23397
Surgical Drain Fluid for Detection of Molecular Residual Disease (MRD) in Patients with Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention:

CLINICAL TRIAL 23420
A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors
Condition: Thoracic
Intervention: BHV-1510 (); Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 23448
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D Mutation
Condition: Multiple
Intervention: Cemiplimab (); Cetuximab (); Erbitux (Cetuximab); Pembrolizumab (Keytruda); QTX3034 (); REGN2810 (Cemiplimab); mFOLFOX6 ()

CLINICAL TRIAL 23480
A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
Condition: Multiple
Intervention: CGT4859 ()

CLINICAL TRIAL 23535
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Amivantamab (); JNJ-61186372 (Amivantamab); JNJ-73841937 (Lazertinib); Lazertinib (); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()

CLINICAL TRIAL 23565
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); paclitaxel ()

CLINICAL TRIAL 23576
A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer
Condition: Thoracic
Intervention: Alimta (Pemetrexed); BNT327 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); paclitaxel ()

CLINICAL TRIAL 23582
A Phase II, multisite, open-label, single arm trial of BNT327 in combination with docetaxel in second-line stage IV non-small cell lung cancer (NSCLC) following chemoimmunotherapy
Condition: Thoracic
Intervention: BNT327 (); Taxotere (docetaxel); docetaxel ()

CLINICAL TRIAL 23580
A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)
Condition: Thoracic
Intervention: BH-30643 ()

CLINICAL TRIAL 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()

CLINICAL TRIAL 23585
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)
Condition: Breast
Intervention: Avastin (Bevacizumab); BBO-10203 (); Bevacizumab (); FOLFOX (); Faslodex (fulvestrant); Herceptin (Trastuzumab); LEE011 (Ribociclib); Ribociclib (); Trastuzumab (); fulvestrant (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 23581
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Atezolizumab (Tecentriq); Durvalumab (); MEDI4736 (Durvalumab); Tarlatamab (AMG 757); YL201 ()

CLINICAL TRIAL 23599
Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers
Condition: Multiple
Intervention: Alimta (Pemetrexed); BBO-11818 (); Cetuximab (); Erbitux (Cetuximab); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin (); cisplatin ()

CLINICAL TRIAL 23584
A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Atezolizumab (Tecentriq); Durvalumab (); Iadademstat (); MEDI4736 (Durvalumab)

CLINICAL TRIAL 23579
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Durvalumab (); MEDI4736 (Durvalumab); Olomorasib/Placebo (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23553
DENALI-1: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod CAR T, in Heterozygous HLA A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA A*02 Expression.
Condition: Immunotherapy
Intervention: A2B395 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23583
Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Condition: Thoracic
Intervention: N-803 (); Taxotere (docetaxel); Tislelizumab (); docetaxel ()

CLINICAL TRIAL 23568
Inequities and Trends in Lung Cancer Screening Among People with HIV in the US
Condition: Thoracic
Intervention:

CLINICAL TRIAL 23656
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.
Condition: Thoracic
Intervention: Alimta (Pemetrexed); BAY 2927088 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin (); cisplatin ()

CLINICAL TRIAL 23659
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Condition: Multiple
Intervention: ARV-806 ()

CLINICAL TRIAL 23683
S2414, A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non-Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT)
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Durvalumab (); MEDI4736 (Durvalumab)

CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Sotorasib (); Trametinib (); VVD-159642 ()

CLINICAL TRIAL 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()

CLINICAL TRIAL 50521
Integrated Plasma Metabolomic and Cytokine Profiling to Characterize Cancer Cachexia
Condition: Thoracic
Intervention: